This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
E Ink in 2008
Yoffie, David B.; Kim, ReneeCase HBS-709443-EStrategyIn the fall of 2008, E Ink had positioned itself as a leader in electronic ink technology thanks to the launch of several eBook devices such as Amazon's Kindle. Yet E Ink still faced the question of how to turn its technology into a profitable business amid competing technologies and financial challenges.Starting at €8.20
-
E Ink en 2008
Yoffie, David B.; Kim, ReneeCase HBS-710S16StrategyEn el otoño de 2008, E Ink ha posicionado como un líder en tecnología de tinta electrónica gracias a la puesta en marcha de varios dispositivos de libros electrónicos como el Kindle de Amazon. Sin embargo, E Ink aún se enfrenta a la cuestión de cómo convertir su tecnología en un negocio rentable en medio de tecnologías de la competencia y los retos financieros.Starting at €8.20
-
E Ink in 2005 (Spanish version)
Yoffie, David B.; Mack, Barbara J.Case HBS-710S15StrategyExplores the challenges of commercializing a bleeding-edge technology. After seven years, E Ink has spent more than $100 million to commercialize electronic ink. With business momentum picking up, but resources running out, the case examines the key trade-offs in bringing a new technology to market.Starting at €8.20
-
Merck: Managing Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109084-EStarting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74
-
Wintel (E): del contacto en múltiples mercados al contacto en diferentes áreas geográficas
Yoffie, David B.Case HBS-706S46StrategyComplementa el caso (A).Starting at €5.74
-
Shanghai Pharmaceuticals
Herzlinger, Regina E.; Kindred, NatalieCase HBS-313016-EStrategyShanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company-essentially a collection of subsidiaries operating under a unified management structure-was formed through the 2009 merger of several state-owned enterprises, part of a broad policy effort in China to streamline state assets, ...Starting at €8.20
-
McKesson
Herzlinger, Regina E.; Kindred, NatalieCase HBS-312002-EMcKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into health care services with the acquisition of U.S. Oncology, an integrated cancer care company, whose expertise it could leverage in offerings catered to other physician specialties. Wi...Starting at €8.20
-
Brasil Foods
Bell, David E.; Kindred, NatalieCase HBS-512013-EStrategyIn mid-2011, the management of Brasil Foods, a leading Brazilian branded foods producer and protein exporter, is evaluating strategies for international and domestic growth. The team has just received approval from Brazil's antitrust authorities to complete the merger of Perdigao and Sadia, the two massive food producers that had combined to form Brasil Foods in 2009. Now, the team is free to focus on their ambitious plan to double revenues by 20...Starting at €8.20
-
Hormel Foods
Bell, David E.; Kindred, NatalieCase HBS-520045-EMarketingIn 2019, CEO Jim Snee is weighing how to shape the image of Hormel Foods, one of the largest U.S. meat and food companies, at a time when the industry faces unprecedented scrutiny. Based in the small town of Austin, Minnesota, the nearly 130-year-old firm is best known for its legacy meat-based brands such as Hormel Pepperoni and Spam. It also owns brands (many acquired recently) that consumers might not associate with Hormel, such as Wholly Guac...Starting at €8.20